Safety signals observed will not yield targeted product profile –
- No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial –
- Oral Factor XIIa program to become primary focus for HAE prophylaxis -
https://finance.yahoo.com/news/kalvista-pharmaceuticals-announces-termination-kvd824-103000419.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.